In a report published Friday, Jefferies & Company reiterated its Hold rating on Allscripts Healthcare Solutions MDRX, and raised its price target from $10.50 to $13.00.
Jefferies noted, “Dismal 3Q results were attributed to customer hesitation on MDRX's a) corporate future and b) NT product future. The acknowledgment of a deal process puts a floor in the stock. Maybe even drives some upside. Many long-awaited releases go GA this month, but NT impact on bookings is questionable. 2012 guidance was withdrawn. A lower go-forward tax rate and share count offset nearly all of our reduction in 2013 pre-tax income.”
Allscripts Healthcare Solutions closed on Thursday at $12.26.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in